Loading
Old version — revision 1
This is a fixed snapshot of Organ shortage, saved by Import as part of the initial corpus import. It is not edited and it is not updated; the article may have changed since.
Edit summary: Initial import of content/organ-shortage.md — the filesystem corpus, unchanged. Not an edit.
The persistent gap between the number of people who need a transplant and the number of usable donated organs, which drives most work on engineered and animal-derived replacements.
Organ shortage is the structural gap between the number of people who would benefit from a transplant and the number of organs available to transplant. It is the practical reason most of the technologies covered elsewhere on this wiki exist: Xenotransplantation, Organ bioprinting, Lab-grown organs and mechanical support such as the Artificial heart are all responses to a supply constraint that donation policy has narrowed but never closed. The shortage is usually described with waiting-list statistics, which understate it, because being on a list requires being sick enough to need an organ and well enough to survive receiving one.
More than a hundred thousand people are registered on the United States transplant waiting list at any time, the large majority of them waiting for a kidney, and federal agencies put the number dying each day while listed at around seventeen. The United States performed a record of more than forty-six thousand transplants in 2023 and volumes have continued to rise since, and yet the list has not shortened, because listing rates rise with capacity.
The list is a poor measure of need. In the United States more than half a million people are on dialysis, several times the number registered for a kidney; the rest are excluded by age, comorbidity, insurance status, or a referral that never happened. For livers, hearts and lungs the equivalent unlisted populations are smaller but real. Internationally the picture is worse: the World Health Organization's donation and transplantation observatory estimates that transplantation meets under a tenth of global need, and many countries have essentially no deceased-donor programme.
Deceased organ donation depends on a rare mode of death. Transplantable organs require perfusion until recovery, which in practice means the donor died in an intensive care unit, either after a determination of death by neurological criteria while a ventilator maintained circulation, or after planned withdrawal of life support with rapid recovery afterwards. Only a small percentage of all deaths occur in circumstances that permit either. Deaths at home, in the community, or after prolonged illness almost never yield organs.
This is what distinguishes organs from blood, the other donated tissue: a healthy adult can give blood repeatedly, which is why the response to blood scarcity has been recruitment and, more recently, the manufactured substitutes discussed in Artificial blood, while the response to organ scarcity cannot be either.
That biological ceiling means consent rates, however improved, operate on a small denominator. Even a country converting every eligible family to donation would not produce enough kidneys to clear its dialysis population, which is why living donation and non-human sources matter.
Organ quality compounds the problem. Donors are older and more comorbid than they were a generation ago, and marginal organs are more likely to be declined. Roughly one in five kidneys recovered in the United States is discarded rather than transplanted, a rate substantially higher than in comparable European systems and one that reflects allocation logistics, cold ischaemia time accumulating during offers, and liability incentives as much as organ quality.1
Consent systems. Presumed consent, or opt-out, is the most discussed reform: donation is assumed unless a person has registered a refusal. Wales adopted it in 2015, England in 2020, Scotland and the Netherlands soon after, and Nova Scotia became the first North American jurisdiction to do so. The evidence that the legal default drives donation rates is weaker than the policy's popularity suggests, and systematic reviews find the association confounded by health-system capacity and mortality patterns.2 Spain has the world's highest deceased-donor rate and an opt-out law, but its rates only rose sharply a decade after the law, following the creation of a national coordination organisation that placed trained transplant coordinators in intensive care units and standardised the family approach.3 Practitioners generally attribute the Spanish result to that infrastructure rather than to the default rule, and in most opt-out countries families are still consulted and can refuse.
Living donation. Living donors supply a large share of kidneys and a smaller share of livers. Paired exchange programmes match incompatible donor-recipient pairs into chains, sometimes dozens long, initiated by a non-directed donor. These have expanded access substantially without new donors, by better matching the ones who exist. Uterus transplantation draws on both living and deceased donors and is unusual in being planned as temporary: the graft is removed once it has supported a pregnancy, so that immunosuppression can stop.
Allocation. How organs are ranked among candidates is a distributional question with no neutral answer: weighting medical urgency, expected years of graft survival, waiting time, and geography produce different winners. Continuous distribution frameworks that replace hard geographic boundaries with weighted scores have been introduced for several organs in the United States. Oversight of the American system itself was restructured by 2023 legislation that ended the single-contractor model under which one organisation had run the national network since the 1980s.
Incentives. United States law prohibits transfer of organs for valuable consideration, and most countries have similar bans. Reform proposals separate removing disincentives — reimbursing lost wages, travel and childcare for living donors, which is now permitted in the United States — from paying donors, which is not. Iran operates the only legal regulated market in living kidney donation and reports having eliminated its waiting list; critics point to evidence that donors are disproportionately poor and that follow-up care is inadequate. The Declaration of Istanbul, adopted in 2008 and revised since, sets the international position against organ trafficking and transplant tourism.
Does paying for organs increase supply or corrupt itProponents of regulated compensation argue that the current system already pays everyone in the operating room except the person supplying the organ, and that a legal market with price floors and follow-up care would be safer than the black market that exists anyway. Opponents argue that payment converts a gift relationship into a transaction that will fall hardest on the poor, that valuation of body parts is corrosive regardless of safeguards, and that the Iranian experience shows exploitation rather than a solution. The disagreement is about values, not primarily about elasticity of supply.
Machine perfusion. The largest recent gain has come from keeping organs alive outside the body rather than cold on ice. Hypothermic oxygenated perfusion and normothermic machine perfusion, which maintains a liver or heart at body temperature and metabolically active, extend the viable window, permit assessment of organ function before implantation, and allow marginal organs to be rescued; a randomised European trial found normothermic liver preservation reduced graft injury and discard compared with static cold storage.4 Portable normothermic systems made routine donation after circulatory death feasible for hearts, an organ that had been recovered almost exclusively from brain-dead donors. The effect on supply has been material and immediate, and unlike engineered organs it required no new biology.
Normothermic regional perfusion, which restores circulation to the donor's abdominal and thoracic organs in situ after circulatory death while occluding the vessels supplying the brain, has raised objections in the United States about whether restoring circulation is compatible with the determination of death that preceded it.
Reducing discard. Better allocation software, earlier offers, and objective viability assessment during perfusion address the fifth of recovered kidneys that is thrown away, which is the cheapest available supply.
New sources. Pig organs from animals edited to remove antigens and add human regulatory proteins have entered clinical trials, with the arithmetic of the kidney list as the explicit rationale. Engineered organs remain preclinical, for the reasons given in Tissue engineering and Decellularized scaffolds. Cell-scale products arrive sooner than organ-scale ones: transplanted islet clusters, built by methods close to those behind Organoids, can restore a specific function without replacing an anatomical structure, and reduce demand for whole-pancreas transplantation before they touch the kidney list.
Supply-side framing obscures that transplant demand is substantially preventable. The dominant causes of kidney failure are diabetes and hypertension; the dominant causes of liver failure now include metabolic dysfunction-associated steatotic liver disease, with viral hepatitis in decline since the arrival of curative hepatitis C therapy. Drugs that slow chronic kidney disease progression, and the metabolic effects of newer weight and glucose therapies, may bend demand curves more than any donation reform. Curative treatment of inherited metabolic liver disease by Somatic gene therapy removes a smaller but real share of the paediatric transplant burden.
The furthest version of the demand-side argument belongs to the Geroscience hypothesis: organ failure is concentrated in later life, so an intervention that slowed the underlying aging process would reduce the incidence of every form of it at once. That claim is unproven in humans, and its economic version is set out in The longevity dividend. It also cuts the other way, since populations that live longer accumulate more organ failure in absolute terms unless morbidity compresses as well, the disputed proposition examined in Compression of morbidity. A transplant system whose list stops growing because fewer organs fail would be a better outcome than one that grows its supply to match.
Whether that happens is the open question. Every previous expansion of supply — expanded criteria donors, donation after circulatory death, machine perfusion — has been absorbed by increased listing rather than a shorter list, which is what makes the shortage structural rather than a temporary deficit, and what keeps Access and inequality central to any discussion of who receives a manufactured organ if one ever arrives.
paperStewart, D. E. et al. "Diagnosing the decades-long rise in the deceased donor kidney discard rate in the United States." Transplantation, 2017. ↩
paperRithalia, A. et al. "Impact of presumed consent for organ donation on donation rates: a systematic review." BMJ, 2009. ↩
paperMatesanz, R. et al. "Spanish experience as a leading country: what kind of measures were taken?" Transplant International, 2011.↩Written from inside the Spanish national transplant organisation about its own programme; it is a descriptive account, not a controlled comparison with other countries.
paperNasralla, D. et al. "A randomized trial of normothermic preservation in liver transplantation." Nature, 2018.↩A multicentre European randomized trial whose primary endpoint was a biochemical marker of graft injury; patient survival was not what it was designed to test.